A Phase 2, Open-Label Study of Sofosbuvir in Combination With PEG and Ribavirin for 12 Weeks in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3
Phase of Trial: Phase II
Latest Information Update: 04 Nov 2014
At a glance
- Drugs Sofosbuvir (Primary) ; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Acronyms LONESTAR-2
- Sponsors Gilead Sciences
- 01 Dec 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 Jun 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 16 Mar 2013 New trial record